Overview
- Blackstone Life Sciences VI, which closed Monday at its $6.3 billion hard cap, is the largest private fund ever raised for life sciences.
- At $6.3 billion, the new vehicle is nearly 40% larger than Blackstone’s $4.6 billion predecessor completed in 2020.
- BXLS, launched in 2018, backs drugs and devices through equity stakes, research funding, royalty deals, and company creation.
- Blackstone says its partnerships have produced 34 approvals and an 86% success rate for late‑stage assets, a record it touts to speed products to patients.
- Recent moves include $400 million for a Teva gut‑disease drug, $700 million to support a Merck cancer therapy with potential royalties, an R&D pact with Johnson & Johnson, and Novartis’ 2025 purchase of Anthos for $3.1 billion.